Abstracts tagged "Lupus nephritis"

Abstract Number: 2905 • 2015 ACR/ARHP Annual Meeting
Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Renal Disease Subcommittee of the American College of Rheumatology (ACR) Ad Hoc Committee on Systemic Lupus Erythematosus (SLE) has recommended the urinary protein level…
Abstract Number: 2913 • 2015 ACR/ARHP Annual Meeting
Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation
Dario Roccatello¹, Savino Sciascia², Daniela Rossi¹, Carla Naretto³, Simone Baldovino³, Mirella Alpa³, Ilaria Salussola³ and Vittorio Modena³, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³CMID, Torino, Italy
Background/Purpose: B-lymphocytes (BL) play a critical role in Systemic Lupus Erythematosus (SLE). BL depletion therapy still remains an attractive option, despite the disappointing results of…
Abstract Number: 2916 • 2015 ACR/ARHP Annual Meeting
Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis
Yoichiro Akiyama, Takeo Sato, Takamasa Murosaki, Katsuya Nagatani, Masahiro Iwamoto and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: Many studies have reported long-term outcomes including morbidity, mortality, and end stage kidney disease (ESKD) in patients with lupus nephritis (LN). We aimed to…
Abstract Number: 2921 • 2015 ACR/ARHP Annual Meeting
Lupus Nephritis: An Exploration of Management Style
Abhishek Nandan¹, Huzaefah Syed², Christen Vagts¹ and Jason Kidd¹, ¹Virginia Commonwealth University Medical Center, Richmond, VA, ²Rheumatology, Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: We aim to evaluate the differences and rationale behind the diagnostic and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and rheumatologists. Methods:…
Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
J. Madison Hyer¹, Bethany Wolf¹, Jim Oates², Gary S. Gilkeson³ and Diane L. Kamen², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Department of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
Abstract Number: 394 • 2015 ACR/ARHP Annual Meeting
Clinical Features of Children with Silent Lupus Nephritis
Hiroyuki Wakiguchi¹, Syuji Takei^2,3, Tomohiro Kubota¹, Yuichi Yamasaki¹, Tsuyoshi Yamatou¹, Yasuhito Nerome¹, Harumi Akaike¹, Yukiko Nonaka¹, Tomoko Takezaki¹, Hiroyuki Imanaka¹ and Yoshifumi Kawano¹, ¹Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshma, Japan
Background/Purpose: Lupus nephritis (LN) is the major findings in systemic lupus erythematosus (SLE). LN with some pathologic findings in the kidney but had normal urine…
Abstract Number: 403 • 2015 ACR/ARHP Annual Meeting
Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
Justin Hung Tiong Tan¹, Sook Fun Hoh², Manasita Tanya¹, Lena Das¹, Ma Thin Mar Win³, Yiong Huak Chan³ and Thaschawee Arkachaisri^1,4, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ³Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁴Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore
Background/Purpose: The time to recovery from proteinuria in patients with lupus nephritis (LN) receiving standard treatment has been described in adult, but not in children.…
Abstract Number: 754 • 2015 ACR/ARHP Annual Meeting
Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide
Alexandra Audemard-Verger¹, Nicolas Martin Silva², Céline Verstuyft³, Nathalie Costedoat-Chalumeau⁴, Aurélie Hummel⁵, Véronique Le Guern⁴, Karim Sacre⁶, Olivier Meyer⁷, Eric Daugas⁸, Cecile Goujard⁹, Audrey Sultan², Thierry Lobbedez², Lionel Galicier¹⁰, Jacques Pourrat¹¹, Claire Le Hello², Michel Godin¹², Remy Morello², Marc Lambert¹³, Eric Hachulla¹³, Philippe Vanhille¹⁴, Guillaume Queffeulou¹⁵, Jacques Potier¹⁵, Jean Jacques Dion¹⁶, P Bataille¹⁷, Dominique Chauveau¹⁸, Guillaume Moulis¹⁹, Dominique Farge²⁰, Pierre Duhaut²¹, Bernadette Saint Marcoux²², Alban Deroux²³, Jennifer Manuzak²⁴, Camille Francès²⁵, Olivier Aumaître²⁶, Holy Bezanahary²⁷, Laurent Becquemont²⁸ and Boris Bienvenu²⁹, ¹Internal Medicine, CHU Caen, caen, France, ²CHU Caen, caen, France, ³Pharmacology, Hopital Bicêtre, Le Kremlin Bicêtre, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Necker, paris, France, ⁶Internal Medicine, Hospital Bichat, Paris, France, ⁷Rheumatology, Hopital Bichat, Paris, France, ⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ⁹Bichat, Paris, France, ¹⁰Clinical Immunology, St Louis Hospital, Paris, France, ¹¹Nephrology, Rangeuil Hospital, Paris, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Lille, Lille, France, ¹⁴Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, Valenciennes, France, ¹⁵Ch Cherbourg, Cherbourg, France, ¹⁶Ch Charleville Mezeiere, Charleville Mezeiere, France, ¹⁷Ch Boulogne sur Mer, Boulogne sur Mer, France, ¹⁸CH Toulouse, Toulouse, France, ¹⁹CHU Purpan, Toulouse, France, ²⁰Internal Medicine, Hopital St Louis, Paris, France, ²¹Department of Internal Medicine and RECIF, CHU Amiens, Amiens, France, ²²CH Aulnay sous Bois, Aulnay sous Bois, France, ²³Internal Medicine, CHU Grenoble, Grenoble, France, ²⁴Institut Cochin, Paris, France, ²⁵Dermatology Service, Tenon Hospital, Paris, France, ²⁶Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²⁷Internal Medicine, University Hospital of Limoges, Limoges, France, ²⁸KB, Paris, France, ²⁹Internal Medicine, Hospital Caen, Caen, France
Background/Purpose: Cyclophosphamide (CYC) is effective in inducing remission of lupus nephritis (LN). CYC, as a pro-drug, requires bioactivation through multiple hepatic cytochrome P450s and glutathione…
Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Anna R. Broder¹, Candace H. Feldman², Anand Kumthekar³, Michail Alevizos⁴, Hongshu Guan⁵, Medha Barbhaiya⁶ and Karen H. Costenbader⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Internal Medicine, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…
Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting
Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis
Jeffrey Hampton¹, Nicholas A. Young², Sudha Agarwal³, Saba Aqel³, Kendra Jones³, Lai-Chu Wu^2,4, Nicole Powell⁵, John Sheridan⁵, Michael Bruss³ and Wael N. Jarjour², ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage. Our group has previously shown that moderate daily exercise reduces systemic inflammation…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Angela Pakozdi¹, Ravindra Rajakariar², Muhammad Magdi Yaqoob² and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
Abstract Number: 1814 • 2015 ACR/ARHP Annual Meeting
Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic infections such as…
Abstract Number: 1611 • 2014 ACR/ARHP Annual Meeting
Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Noémie Jourde-Chiche Sr.¹, Stéphane Burtey², Nathalie Bardin³, Elizabeth Whalen⁴, Bertrand Gondouin⁵, Scott Presnell⁶, Bertrand Dussol⁷, Gilles Kaplanski⁸, Jean-Robert Harle⁹, Yvon Berland², Virginia Pascual¹⁰, Damien Chaussabel⁴ and Laurent Chiche¹¹, ¹Nephrology, Aix-Marseille Université - APHM, Marseille, France, ²Nephrology, APHM, Marseille, France, ³Hopital de la Conception, Marseille, France, ⁴BRI, seattle, WA, ⁵Department of Nephrology, APHM, Marseille, France, ⁶bri, seattle, WA, ⁷AP Marseille, Marseille, France, ⁸INSERM U608, Marseille, France, ⁹Internal Medicine, APHM, Marseille, France, ¹⁰Baylor University, Dallas, TX, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France
Background/Purpose: Lupus nephritis (LN) is a serious complication of SLE. Reliable biomarkers to assess and/or predict renal involvement in SLE patients are needed. The aim…
Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting
Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Joyce S Hui-Yuen¹, Kristi Truong², Liza Mariel Bermudez-Santiago¹, Amy J. Starr³, Andrew Eichenfield⁴, Lisa F. Imundo⁵ and Anca Askanase³, ¹Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center, New York, NY, ²Doctor of Pharmacy degree program, St John's University, Queens, NY, ³Columbia University Medical Center, New York, NY, ⁴Div of Pediatric Rheumatology, Children's Hosp of New York, New York, NY, ⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY
Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.